<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selection of etiology-based antiemetics in palliative care</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selection of etiology-based antiemetics in palliative care</h1>
<div class="graphic"><div class="figure"><div class="ttl">Selection of etiology-based antiemetics in palliative care</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="25%"></colgroup><colgroup width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Situation</td> <td class="subtitle1">Associated neurotransmitters</td> <td class="subtitle1">Recommended antiemetic</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Cancer patients</td> </tr> <tr> <td class="indent1">No definite etiology (not related to chemotherapy or radiation, constipation, central nervous system disease, metabolic abnormalities/drugs, or bowel obstruction)</td> <td>Dopamine, serotonin (type 3 receptor [5HT3] and type 4 receptor [5HT4]), acetylcholine (muscarinic)</td> <td> <p><strong>First line:</strong> Metoclopramide 10 mg every 4 hours orally or subcutaneously; if insufficient relief with intermittent dosing, may switch to an intravenous or subcutaneous continuous infusion (starting at 30 to 40 mg per 24 hours, increasing to 2.5 to 5 mg/hour infusion [maximum 60 to 120 mg/day]) if needed for relief. A nasal formula is also available, dosed as 1 spray (15 mg) in 1 nostril 4 times daily (30 minutes prior to each meal and at bedtime).</p> <strong>Second line:</strong> Add 5HT3 receptor antagonist* or substitute dopamine receptor antagonist (chlorpromazine 10 to 25 mg every 4 to 8 hours orally, 10 to 25 mg every 3 to 4 hours intravenously, or 25 mg initially, followed by 10 to 25 mg every 3 to 4 hours intramuscularly; prochlorperazine 5 to 25 mg every 6 to 8 hours orally, intramuscularly, or rectally (where available); or haloperidol 0.5 to 2 mg every 6 to 8 hours orally, intravenously, or subcutaneously) or olanzapine 2.5 to 5 mg every 12 hours orally or sublingually.</td> </tr> <tr> <td class="indent1">Chemotherapy-induced nausea and vomiting (CINV)</td> <td>5HT3, neurokinin-1</td> <td><strong>First line:</strong> <ol class="decimal_heading"> <li>5HT3 receptor antagonist* </li> <li>Neurokinin-1 antagonist<sup>¶</sup> </li> <li>Dexamethasone </li> </ol> <strong>Second line:</strong> Other drugs with a lower therapeutic index, including dopamine receptor antagonist<sup>Δ</sup>, metoclopramide, nabilone, or dronabinol.</td> </tr> <tr> <td class="indent1">Radiation therapy-induced nausea and vomiting</td> <td>5HT3, dopamine</td> <td><strong>First line:</strong> <ol class="decimal_heading"> <li>5HT3 receptor antagonist* </li> <li>Dexamethasone </li> </ol> <strong>Second line:</strong> Dopamine receptor antagonist.<sup>Δ</sup></td> </tr> <tr> <td class="indent1">Gastroparesis</td> <td>Dopamine, 5HT3, 5HT4, acetylcholine (muscarinic)</td> <td> <p><strong>First line:</strong> Metoclopramide 5 to 10 mg 4 times daily intravenously, orally, or subcutaneously. A nasal formula is also available, dosed as 1 spray (15 mg) in 1 nostril 4 times daily (30 minutes prior to each meal and at bedtime).</p> <p><strong>Second line:</strong> Mirtazapine or erythromycin.</p> Third line: Domperidone (limited availability in the United States) or cisapride (limited availability in the United States).</td> </tr> <tr> <td class="indent1">Bowel obstruction<sup> </sup>(inoperable)◊</td> <td>Dopamine, somatostatin, acetylcholine (muscarinic)</td> <td> <p><strong>First line:</strong> Haloperidol 0.5 to 2 mg every 6 to 8 hours orally, intravenously, or subcutaneously and titrate up to 20 mg/day if needed; also add dexamethasone 4 mg every 12 hours intravenously or subcutaneously; and octreotide 0.1 mg every 8 hours intravenously or subcutaneously up to 0.3 mg every 8 hours, depending on response; scopolamine (hyoscine) butylbromide (where available) 20 mg SC followed by 60 mg per day as a continuous SC infusion; or transdermal scopolamine.</p> <strong>Second line:</strong> Chlorpromazine, prochlorperazine, or cyclizine subcutaneously (not chlorpromazine), rectally (only for prochlorperazine, where available), or intravenously.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Nausea due to intracranial malignancy (primary or secondary brain tumor)</td> <td>Unknown</td> <td><strong>First line:</strong> Dexamethasone 10 mg loading dose, followed by 4 mg every 6 hours or 8 mg every 12 hours, orally or intravenously.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Nausea due to non-cancer conditions</td> </tr> <tr> <td class="indent1">Kidney failure</td> <td> </td> <td>Haloperidol (decrease dose by 50%).</td> </tr> <tr> <td class="indent1">Liver failure</td> <td> </td> <td>Metoclopramide at 60 mg per 24 hours appears to be safe and does not increase sedation in mild encephalopathy.</td> </tr> <tr> <td class="indent1">Chronic obstructive pulmonary disorder (COPD)</td> <td> </td> <td>No specific recommendations, but in view of association with GERD, a prokinetic such as metoclopramide is reasonable.</td> </tr> <tr> <td class="indent1">Heart failure</td> <td> </td> <td>No specific recommendation; however, use ondansetron or metoclopramide with caution.</td> </tr> <tr> <td class="indent1">Human immunodeficiency virus (HIV)</td> <td> </td> <td> <p>Often related to antiretroviral medication. No specific antiemetic recommendation; however, patients with HIV on metoclopramide may be at increased risk of EPS.</p> Consider the cannabinoid dronabinol in patients who also have a poor appetite (initial dose 2.5 mg twice daily before lunch and dinner and titrate up to a maximum of 20 mg/day).</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>GERD: gastroesophageal reflux disease; EPS: extrapyramidal symptoms.<br/>* 5HT3 receptor antagonists: granisetron, ondansetron, palonosetron, dolasetron, tropisetron, ramosetron.<br/>¶ Neurokinin-1 antagonists: aprepitant, fosaprepitant.<br/>Δ Dopamine receptor antagonists: chlorpromazine, haloperidol, prochlorperazine.<br/>◊ Metoclopramide might be helpful if the bowel obstruction is partial. Do not use in patients with a confirmed or suspected complete mechanical obstruction.</p></div><div class="graphic_reference">Adapted and expanded from: Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. Am Fam Physician 2004; 69:1169.</div><div id="graphicVersion">Graphic 91324 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
